Researchers developed a double-network hydrogel designed to deliver KPV (a tripeptide derived from α-melanocyte-stimulating hormone) to the colon in an animal model of inflammatory bowel disease, demonstrating that the hydrogel improved markers of mucosal barrier function and reduced inflammation in inflamed colon tissue. The hydrogel formulation was engineered to provide sustained KPV release and enhanced adhesion to the intestinal mucosa compared to free KPV alone. **Evidence level: Animal model**